Stroke drug development is shifting from broad anticoagulation and single-target neuroprotection toward precise targets and combination designs. Ischemic stroke accounts for over 80 percent of cases worldwide. Reperfusion improved acute care, yet bleeding risk and failed neuroprotection remain unresolved. In the fourth quarter of 2026 the first factor XIa inhibitor was approved in China and the United States, validating precision anticoagulation. The clinical gap that drives stroke drug development Stroke remains a leading cause of adult disability and death worldwide, and ischemic stroke accounts for over 80 percent of cases. Progress over the past three decades has come mainly from reperfusion: a clearer time window for intravenous thrombolysis, and the spread of endovascular thrombectomy. Both restore blood flow. Neither solves the drug-level problems that follow. In secondary prevention, clinicians still trade recurrence reduction against intracranial and gastrointestinal bleeding....
Antiviral API for CMV infections



